During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its projected EPS growth exceeds 115%. Thursday’s results will test whether that ...

Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in ...

DiVincenzo explained that QX700 is "enabling Bio-Rad to expand its served market and gain share in the entry-level digital PCR segment," and that process chromatography delivered over 20% growth in ...

Q1 2025 Management View CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz ...

Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, given the demand for its quality control and immunology products in Clinical Diagnostics. In addition, growth across ...